Gabapentin

Drug Profile

Gabapentin

Alternative Names: CI 945; GOE 3450; Neurontin

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Pfizer
  • Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Epilepsy; Neuralgia; Neuropathic pain; Postherpetic neuralgia
  • Discontinued Amyotrophic lateral sclerosis; Anxiety disorders; Bipolar disorders; Migraine; Spinal muscular atrophy

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 09 Jun 2010 First generic equivalent approved in USA for Postherpetic neuralgia
  • 26 Jul 2006 Registered for Epilepsy in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top